Skip to content

Study · In vitro (cells) · rat · 1988

4 results

A cellular basis for functionally releasable pools in somatotropes.

Chao CC, Hoeffler JP, Frawley LS

Life sciences1 Jan 1988Cited by 8 (Europe PMC)

PMID3123835 (opens in a new tab)DOI10.1016/0024-3205(88)90462-6 (opens in a new tab)PepBankPUB-03123835
Publisher pagePubMedAsk about this study
Jump to 4 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study4

4 results from studies that gave the peptide. No result from this study comes from people.

  1. 01LabIn vitro (cells)Efficacy outcome

    In neonatal rat pituitary cells, GHRP‑6 influenced plaque formation in only half the somatotropes, whereas GRF affected almost all.

    In plain wordsIn cells from neonatal rats, GHRP‑6 affected hormone release in fewer cells than GRF.

    Peptide
    GHRP-6
    Outcome
    DecreaseProportion of somatotropes with accelerated plaque formation
    Study

    ratn: not reported in source

    monodispersed anterior pituitary cells from neonatal male rats
    Comparator
    GRF
    Outcome group
    Growth hormone and IGF-1 · Endocrine and hormones
    Studied dose
    Dose not stated

    Source sentences

    Summary
    GRF increased the rate of plaque formation (an index of the rate of hormone release) from almost all somatotropes, whereas GHRP-6 influenced only half of these cells.
    1 context sentence
    Summary · context
    Monodispersed anterior pituitary cells from neonatal male rats were subjected to reverse hemolytic plaque assays for GH in the presence or absence of GH-releasing peptide (GHRP-6, an enkephalin-like hexapeptide) and rat GH-releasing factor (GRF).
  2. 02LabIn vitro (cells)Efficacy outcome

    In neonatal rat somatotropes, GHRP‑6 and untreated cells had virtually superimposable plaque-size distributions after incubation.

    In plain wordsIn cells from neonatal rats, GHRP‑6 produced a final hormone-release distribution similar to untreated cells.

    Peptide
    GHRP-6
    Outcome
    No significant changeCumulative GH release distribution
    Study

    ratn: not reported in source

    monodispersed anterior pituitary cells from neonatal male rats
    Comparator
    untreated somatotropes
    Outcome group
    Growth hormone and IGF-1 · Endocrine and hormones
    Studied dose
    Dose not stated · 4 hAs given in this study (rat).

    Source sentences

    Summary
    This pattern contrasted with those of untreated and GHRP-6 treated somatotropes which each produced unimodal frequency distributions that were skewed to the left (toward smaller plaques) and were virtually superimposable at the end of a 4 h incubation.
    1 context sentence
    Summary · context
    Monodispersed anterior pituitary cells from neonatal male rats were subjected to reverse hemolytic plaque assays for GH in the presence or absence of GH-releasing peptide (GHRP-6, an enkephalin-like hexapeptide) and rat GH-releasing factor (GRF).
  3. 03LabIn vitro (cells)Efficacy outcome

    In neonatal rat somatotropes, GHRP‑6 accelerated attainment of the final plaque-size distribution.

    In plain wordsIn cells from neonatal rats, GHRP‑6 reached the final hormone-release distribution faster than untreated cells.

    Peptide
    GHRP-6
    Outcome
    IncreaseRate of attaining final plaque-size distribution
    Study

    ratn: not reported in source

    monodispersed anterior pituitary cells from neonatal male rats
    Comparator
    untreated somatotropes
    Outcome group
    Growth hormone and IGF-1 · Endocrine and hormones
    Studied dose
    Dose not stated

    Source sentences

    Summary
    However, GHRP-6 greatly accelerated the rate at which the final size distribution pattern was attained.
    2 context sentences
    Summary · context
    This pattern contrasted with those of untreated and GHRP-6 treated somatotropes which each produced unimodal frequency distributions that were skewed to the left (toward smaller plaques) and were virtually superimposable at the end of a 4 h incubation.
    Summary · context
    Monodispersed anterior pituitary cells from neonatal male rats were subjected to reverse hemolytic plaque assays for GH in the presence or absence of GH-releasing peptide (GHRP-6, an enkephalin-like hexapeptide) and rat GH-releasing factor (GRF).
  4. 04LabIn vitro (cells)Efficacy outcome

    In neonatal rat pituitary cells, GHRP‑6 produced a unimodal plaque-size distribution, whereas GRF produced a bimodal distribution.

    In plain wordsIn cells from neonatal rats, GHRP‑6 produced one peak in hormone-release amounts, whereas GRF produced two peaks.

    Peptide
    GHRP-6
    Outcome
    Not applicableCumulative GH release distribution versus GRF
    Study

    ratn: not reported in source

    monodispersed anterior pituitary cells from neonatal male rats
    Comparator
    GRF
    Outcome group
    Growth hormone and IGF-1 · Endocrine and hormones
    Studied dose
    Dose not stated

    Source sentences

    Summary
    This pattern contrasted with those of untreated and GHRP-6 treated somatotropes which each produced unimodal frequency distributions that were skewed to the left (toward smaller plaques) and were virtually superimposable at the end of a 4 h incubation.
    2 context sentences
    Summary · context
    Analysis of plaque sizes (which provides a relative index of the cumulative amount of hormone released per cell) revealed that GRF produced a bimodal frequency distribution of plaque sizes, demonstrating that some somatotropes released more hormone than others after treatment with a maximal dose of this secretagogue.
    Summary · context
    Monodispersed anterior pituitary cells from neonatal male rats were subjected to reverse hemolytic plaque assays for GH in the presence or absence of GH-releasing peptide (GHRP-6, an enkephalin-like hexapeptide) and rat GH-releasing factor (GRF).

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    21 Oct 2026, 15:59 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 03:13 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

PepBank is a research reference. Talk to a doctor before you use any peptide.